The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Future of ToxicologyMetabolic Activation and Drug Design: Challenges and Opportunities in Chemical Toxicology
Abstract
The issue of chemically reactive drug metabolites is one of growing concern in the pharmaceutical industry inasmuch as some, but not all, reactive intermediates are believed to play a role as mediators of drug-induced toxicities. While it is now relatively straightforward to identify these short-lived electrophilic species through appropriate in vitro "trapping" experiments, our current understanding of mechanistic aspects of xenobiotic-induced toxicities is such that we cannot predict which reactive intermediates are likely to cause a toxic insult and which will be benign. Little is known about the identities of the macromolecular targets (primarily proteins) of these electrophiles or the functional consequences of their covalent modification by reactive drug metabolites. As a result, several companies have adopted approaches to minimize the potential for metabolic activation of drug candidates at the discovery/lead optimization phase as a default strategy. However, research leading to a deeper insight into mechanistic aspects of toxicities caused by reactive drug metabolites will aid greatly in the rational design of drug candidates with superior safety profiles and represents a challenging and exciting opportunity for chemical toxicology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationAlternative (non-animal) methods for cosmetics testing: current status and future prospects—2010
Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Andersen, K. E., Angers-Loustau, A., Aptula, A., Bal-Price, A., et al. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0693-2 · Cited by 584
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Self-citationPhotoredox-catalyzed deuteration and tritiation of pharmaceutical compounds
Loh, Y. Y., Nagao, K., Hoover, A. J., Hesk, D., Rivera, N. R., Colletti, S. L., Davies, I. W., & MacMillan, D. W. C. (2017) · Science · doi:10.1126/science.aap9674 · Cited by 574
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
Metadata
- Authors
- Baillie, T. A.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-05-28
- Volume
- 19
- Issue
- 7
- Pages
- 889-893
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2086054530
- Cited by
- 160
- References
- 2
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.